(Q24201758)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

meta-analysis

0 references

title

Maintenance chemotherapy for ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

0 references

1 reference

Ling Mei

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Hui Chen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Dong Mei Wei

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Fang Fang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Guan J Liu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Huan Yu Xie

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Xun Wang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Juan Zou

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Xu Han

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Dan Feng

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

publication date

29 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

4 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

page(s)

CD007414

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study

4 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

Improved Overall Survival with 12 Cycles of Single-Agent Paclitaxel Maintenance Therapy following a Complete Response to Induction Chemotherapy in Advanced Ovarian Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

Treatment options in the management of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

Challenges for chemotherapy in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

Ovarian cancer treatment: what is new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

First-line therapy for ovarian carcinoma: what's next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

Maintenance chemotherapy for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation

21 January 2018

1 reference

12 December 2020

A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study

1 reference

12 December 2020

Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatme

1 reference

12 December 2020

Assessing and presenting summaries of evidence in Cochrane Reviews

1 reference

12 December 2020

Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group

1 reference

12 December 2020

Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer

1 reference

12 December 2020

A pilot study of three-cycle consolidation chemotherapy with paclitaxel and platinum in epithelial ovarian cancer patients with clinical complete response after paclitaxel and platinum chemotherapy.

1 reference

12 December 2020

Incorporation of pazopanib in maintenance therapy of ovarian cancer

1 reference

12 December 2020

A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer

1 reference

12 December 2020

Maintenance chemotherapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007414.PUB3

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD007414.PUB3

2 references

Consolidated OpenCitations Corpus – April 2017

1232854

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1232854

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23813336%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

PubMed publication ID

23813336

2 references

Consolidated OpenCitations Corpus – April 2017

1232854